Granules India gets licence from DRDO to manufacture and market COVID-19 drug

Drug firm Granules India on Thursday said it has received licence from Defence Research & Development Organisation (DRDO) to manufacture and market COVID-19 treatment drug, 2- Deoxy-D-Glucose (2-DG).

migrator

Published:2nd Sep, 2021 at 6:28 PM

New Delhi

Developed by DRDO, 2-DG has been granted permission by Drug Controller General of India (DCGI) for emergency use as adjunct therapy in moderate to severe COVID-19 patients, Granules India said in a filing to BSE.

''Granules is working closely with DRDO team to launch the product in India at the earliest,'' it added. The drug reduces a patient's average recovery time by two and half days and oxygen demand by up to 40 percent, the filing said. Shares of Granules India closed at Rs 344.20 per scrip on BSE, down 0.22 percent from the previous close.

Visit news.dtnext.in to explore our interactive epaper!

Download the DT Next app for more exciting features!

Click here for iOS

Click here for Android

Granules India gets licence from DRDO to manufacture and market COVID-19 drug

Drug firm Granules India on Thursday said it has received licence from Defence Research &amp; Development Organisation (DRDO) to manufacture and market COVID-19 treatment drug, 2- Deoxy-D-Glucose (2-DG).

Also Read

PMK removes Anbumani Ramadoss from party, reinstates Dr Ramadoss as party leader

Unnao rape case: SC stays Delhi HC order suspending Sengar's life sentence

Definition of Aravalli hills and ranges: SC keeps in abeyance its November 20 directions

Indonesia: 16 killed in nursing home fire in Manado; victim identification underway

TN under grip of alcohol, violent crimes against women are on the rise: TN BJP

Drug firm Granules India on Thursday said it has received licence from Defence Research & Development Organisation (DRDO) to manufacture and market COVID-19 treatment drug, 2- Deoxy-D-Glucose (2-DG).